Compare Skyworks Solutions Inc (SWKS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Skyworks Solutions Inc trades at $76.5 (market cap $12.15B), while Vertex Pharmaceuticals Incorporated trades at $510.07 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.5× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SWKS | VRTX | |
|---|---|---|
Market Cap | $12.15B | $127.55B |
Volume | 7,390,810 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $91.45 | $557.96 |
52-Week Low | $52.50 | $407.37 |
Typical Hold Time | 50 Days | 120 Days |
Enterprise Value | $12.03B | $121.68B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $83.43, up 0.88% on the day, with a neutral technical signal despite bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue and net income margins have declined year-over-year. The pending Qorvo merger, expected to close in 2026, represents a significant strategic move with $500 million in projected synergies, driving recent stock momentum and analyst optimism.
The investment case balances merger synergies and market expansion against declining profitability and integration risks. With 60% of analysts rating SWKS a Buy and a consensus price target of $78.80 (below current price), near-term upside appears limited. Key risks include execution of the Qorvo integration, competitive pressures in semiconductors, and macroeconomic headwinds affecting consumer electronics demand.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
